Geficent250 mg

Geficent 250 mg is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.... Read more

Targeted Cancer Therapy

Geficent 250 mg inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Geficent 250 mg is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation.

The recommended dose of Geficent 250 mg is 250 mg orally once daily with or without food until disease progression or unacceptable toxicity. Do not take a missed dose within 12 hours of the next dose.

Concomitant use with CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, barbiturates) may reduce serum Geficent 250 mg levels. Plasma concentrations may be increased with potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole). Increased INR or bleeding events with warfarin. May increase plasma levels of metoprolol. May exacerbate vinorelbine-induced neutropenia. Decreased plasma levels and potential reduction in efficacy with drugs that affect gastric pH (e.g. PPIs, H2-receptor antagonists).

Hypersensitivity. Lactation.

Common side effects are pruritus, rash, angioedema, urticaria, epistaxis, haematuria, alopecia, dry mouth and skin, nausea, vomiting, anorexia, stomatitis, diarrhoea, nail disorders, asthenia, pyrexia, proteinuria, eye pain, corneal erosion or ulcer, aberrant eyelash growth and elevations in blood creatinine. Rarely, pancreatitis, erythema multiforme, toxic epidermal necrolysis, corneal membrane sloughing, ocular ischemia, or ocular haemorrhage.

Pregnancy category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Interstitial lung disease (ILD): ILD occurred in patients taking Geficent 250 mg. Geficent 250 mg should be withheld for worsening of respiratory symptoms. It should be discontinued if ILD is confirmed.Hepatotoxicity: Periodic liver function testing should be performed. Geficent 250 mg should be withheld for Grade 2 or higher for ALT and/or AST elevations. It should be discontinued for severe hepatic impairment.Gastrointestinal perforation: Geficent 250 mg should be discontinued for gastrointestinal perforation. Diarrhea: Geficent 250 mg should be withheld for Grade 3 or higher diarrhea.Ocular Disorders including Keratitis: Geficent 250 mg should be withheld for signs and symptoms of severe or worsening ocular disorders including keratitis. It should be discontinued for persistent ulcerative keratitis.Bullous and Exfoliative Skin Disorders: Geficent 250 mg should be withheld for Grade 3 or higher skin reactions or exfoliative conditions.Embryo-fetal Toxicity: Geficent 250 mg can cause fetal harm. Potential risk of Geficent 250 mg to a fetus should be advised and effective contraception should be used.

Store between 20-25° C.

Pediatric Use: The safety and effectiveness of Geficent 250 mg in pediatric patients have not been established.Geriatric Use: No overall differences in safety were observed between patients 65 years and older and those younger than 65 years. There is insufficient information to assess for differences in efficacy between older and younger patients.Administration to patients who have difficulty swallowing solids: Immerse Geficent 250 mg tablets in 4 to 8 ounces of water by dropping the tablet in water, and stir for approximately 15 minutes. Immediately drink the liquid or administer through a naso-gastric tube. Rinse the container with 4 to 8 ounces of water and immediately drink or administer through the naso-gastric tube.